The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Regarding General Meeting

2 Sep 2014 07:00

RNS Number : 5692Q
Plethora Solutions Holdings PLC
02 September 2014
 



 

 

2 September 2014

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

 

Further Regarding General Meeting

 

 

Further to the announcement made on 29 August 2014, Plethora Solutions Holdings plc (AIM: PLE) announces that the Company has posted a new Notice of General Meeting to Shareholders, which is intended to be in substitution for that attached to the Circular letter dated 29 August 2014. The new Notice of General Meeting to Shareholders will be made available on the Company's website, www.plethorasolutions.co.uk.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die. Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting to be held on 18 September 2014.

 

All terms defined in that letter dated Friday, 29 August 2014 have the same meaning when used in this announcement. Shareholders and investors should read the whole text of this announcement.

 

 

Background

 

The Chairman of the Company wrote to Shareholders on Friday, 29 August 2014 in order, inter alia, to convene a General Meeting of shareholders to pass the necessary shareholders resolutions to approve the matters referred to in that Circular letter.

 

Unfortunately, the Notice of General Meeting attached to that Circular letter contained some minor printing errors. Because the Notice of General Meeting is a formal document, it is necessary to issue a new Notice of General Meeting intended to be in substitution for that attached to the Circular letter dated 29 August 2014.

 

Accordingly, a new Notice of General Meeting in which the printing errors have been corrected together with a replacement proxy card for use in relation to the Notice of General Meeting has been sent to Shareholders.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die.

 

Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

 

Action to be Taken

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting. Whether or not Shareholders intend to attend the replacement General Meeting Shareholders are requested to complete the replacement Form of Proxy in accordance with the instructions printed on it and to return it to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, as soon as possible, and in any event so as to arrive no later than 10:00am on 16 September 2014.

 

If Shareholders hold their Ordinary Shares in CREST they may appoint a proxy using the CREST proxy appointment service by following the instructions in note (6) to the replacement Notice of General Meeting. The completion and return of a Form of Proxy, or the electronic appointment of a proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

 

 

Recommendation

 

The Directors believe that the Placing & Subscription, and therefore the Resolutions set out in the replacement Notice of General Meeting, are in the best interests of the Company and Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote in favour of those Resolutions, as they intend to do in respect of their own shareholdings, which in aggregate total 131,949,742 Ordinary Shares representing approximately 31.8% of the existing issued ordinary share capital of the Company.

 

-Ends-

 

Enquiries:

Plethora Solutions

Jim Mellon, Chairman

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

Greg Bailey, NXD

 

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

Emma Earl / Alex Brearley (Nomad)

Martin Lampshire (Broker)

 

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

Niall Pearson

 

Tel: +44(0) 20 3713 4581

Tel: +44(0) 20 3713 4582

Tel: +44(0) 20 3713 4583

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

 

About PSD502™ & Premature Ejaculation:

 

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURUAOURSVAKRUR
Date   Source Headline
15th Mar 20132:57 pmRNSHolding(s) in Company
25th Feb 201311:07 amRNSStrategic review of The Urology Company Limited
14th Feb 20137:00 amRNSFinancing Update
5th Feb 201312:24 pmRNSRelated Party Transaction
5th Feb 20138:19 amRNSFinancing Update
7th Nov 20124:58 pmRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
29th Jun 201211:55 amRNSReport & Accounts
29th Jun 20127:00 amRNSTotal Voting Rights
26th Jun 20125:15 pmRNSHolding(s) in Company
15th Jun 20124:11 pmRNSIssue of Equity - Directors' Interest
14th Jun 201212:05 pmRNSSubscription of Shares
24th Apr 201212:00 pmRNSChange of Registered Office
29th Mar 20127:00 amRNSPreliminary Results
15th Mar 20127:00 amRNSPSD502 Regulatory Submission Update
23rd Jan 20127:01 amRNSTrading Statement
20th Jan 20127:00 amRNSProduct Launch
6th Jan 20127:00 amRNSDirectorate Change
19th Dec 20117:00 amRNSProduct Update
31st Oct 20116:04 pmRNSTotal Voting Rights
14th Oct 20111:23 pmRNSResult of General Meeting
30th Sep 20117:00 amRNSHalf Yearly Report
28th Sep 20117:00 amRNSProposed Financing & Reduction of Debt
28th Sep 20117:00 amRNSAmendment to PSD502 Agreements
25th Jul 20117:00 amRNSStriant® SR commercial update
20th Jul 201112:09 pmRNSTrading Update
6th Jul 20111:24 pmRNSResult of AGM
24th Jun 20112:36 pmRNSReport and Accounts
20th Jun 20117:00 amRNSRe Agreement
9th Jun 201110:00 amRNSResignation of Dr Steven Powell
4th May 20117:00 amRNSExpansion of UK Sales Force
3rd May 20113:48 pmRNSTotal Voting Rights
28th Apr 20114:02 pmRNSDirector/PDMR Shareholding
28th Apr 20112:00 pmRNSHolding(s) in Company
20th Apr 20114:05 pmRNSResult of EGM
15th Apr 20117:00 amRNSHyalofemme Product Update
1st Apr 20117:00 amRNSFinal Results
1st Apr 20117:00 amRNSPlacing
14th Mar 20117:00 amRNSRe Agreement
11th Mar 20112:52 pmRNSDirectorate Change
24th Feb 201112:02 pmRNSHolding(s) in Company
3rd Feb 20119:48 amRNSDirector/PDMR Shareholding
3rd Feb 20117:00 amRNSTrading Update
28th Jan 20113:47 pmRNSHolding(s) in Company
22nd Dec 20104:42 pmRNSHolding(s) in Company
20th Dec 201010:24 amRNSResult of Meeting
20th Dec 20107:00 amRNSExpansion of Product Portfolio
3rd Dec 20107:05 amRNSBusiness Update & Proposed Placing
3rd Dec 20107:00 amRNSProduct Update
17th Nov 20107:01 amRNSLaunch of 3 New Products

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.